NICE appraisal of the obesity pill stays open in the UK

Britain's National Institute for Health and Care Excellence (NICE) has not finished its cost-effectiveness review of orforglipron, the oral GLP-1 drug Eli Lilly sells under the brand name Foundayo. After its first committee meeting, NICE asked Lilly for more information and has not set a date for a second review ^[1]. The appraisal listing still shows an expected publication date of November 18, 2026, but that date depends on how quickly the requested information comes back ^[1].

This NICE review only affects whether the UK's National Health Service will pay for orforglipron. The drug itself is not in question in the US. Orforglipron already has UK marketing authorization: Britain's medicines regulator, the MHRA, approved it on August 10, 2026, making the UK the first country in Europe to authorize the tablet for weight management and type 2 diabetes ^[1]. But authorization and NHS funding are separate steps in Britain's system. Until NICE finishes its review, UK patients can only get orforglipron through a private prescription, at a private price Lilly has set around £100 to £120 per month ^[1]. Lilly began UK private supply on August 24, 2026 ^[1].

For context, orforglipron works differently from injectable GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. It is a small-molecule pill rather than a peptide, so it survives digestion and can be taken once daily at any time, without food or water restrictions ^[1]. Dosing starts at 0.8 mg and moves up through five more steps to a top dose of 17.2 mg, with patients typically staying at each level for at least a month ^[1]. Reported side effects include nausea, constipation, diarrhea, vomiting, dyspepsia, and abdominal pain ^[1].

In the US, the FDA has a separate track from the UK's. The FDA approved orforglipron for obesity in April 2026, and Lilly submitted the drug for a type 2 diabetes indication in the US during the second quarter of 2026 ^[1]. That means American patients already have access to an approved oral GLP-1 option through the normal US prescribing and insurance system, independent of what happens with the UK's NHS coverage decision.

Why it matters for patients

For US readers, the NICE delay is not a US access issue. It does not change FDA approval status, US prescribing rules, or US insurance coverage for orforglipron. What it does show is how differently drug access can work across countries even for the same medicine. In the UK, a drug can be legally approved and still be unavailable through public healthcare until a separate cost-effectiveness body signs off. In the US, coverage instead depends on individual insurance plans, formularies, and prior authorization rules, which follow FDA approval more directly but vary company by company.

The delay also matters if it signals broader questions about how orforglipron's cost and benefit are being weighed by a national health system. NICE's request for more information suggests the agency wants additional data before deciding if the tablet's price is justified for widescale public funding. Whatever NICE ultimately decides, that judgment applies to UK public coverage, not to US market status.

What happens next

NICE's appraisal listing still points to November 18, 2026 as its expected publication date, but no second committee meeting has been scheduled, and that date could move ^[1]. Separately, and unrelated to this UK process, Lilly's application to add a type 2 diabetes indication for orforglipron in the US remains under FDA review after being submitted in the second quarter of 2026 ^[1].